Use of factor IX concentrates in active teenagers with hemophilia B.
This paper addresses issues specific to the treatment of teenagers with hemophilia B. All teenagers, including those with hemophilia, are at high risk of being exposed to accident-related trauma because of activities inherent within normal adolescent development. To reduce the impact of recurrent joint bleeds, studies have shown that prophylaxis should be started at an early age, with treatment individualized due to variability in patient pharmacokinetics and product recoveries. A key factor in the acceptance and success of prophylaxis in teenagers is the training given at hemophilia treatment centers regarding self-treatment dosing and infusion schedules. Both plasma-derived and recombinant products are appropriate in this cohort, depending on the patient's and family's experiences and preferences.
Tagariello
Giuseppe
G
Castelfranco Veneto Haemophilia Centre, Italy. tagariello@ulssasolo.ven.it
D000293:Adolescent; D005164:Factor IX / Q000627:therapeutic use*; D002836:Hemophilia B / Q000628:therapy*; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D011292:Premedication; D014947:Wounds and Injuries
D005164:Factor IX